Plasma renin and cardiovascular risk: What is the evidence for an association?

Massimo Volpe, Thomas Unger

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Renin is a key component of the renin-angiotensin system (RAS), which plays an important role in the maintenance of blood pressure and electrolyte-volume homeostasis. RAS also plays a role in cardiovascular (CV) disease as a result of effects on inflammation and oxidative stress. There is growing evidence that plasma renin activity may be a marker of CV risk in hypertensive patients. This increase in CV risk likely reflects activation of the RAS as a whole. Patients undergoing treatment for hypertension experience a reactive increase in renin, especially if treated with diuretics, vasodilators or agents that block the RAS. There is not sufficient evidence, however, that this reactive increase in renin is intrinsically harmful for hypertensive patients in whom adequate levels of RAS blockade have been achieved. Indeed, in such patients, additional RAS blockade may not be beneficial and may even increase the risk of adverse events. Plasma renin may be an important prognostic indicator in untreated patients, and one that can be used to help in the choice of antihypertensive treatment. Currently, however, the link between plasma renin and CV risk in treated patients is inconsistent between different populations and in various clinical conditions, calling for further investigation.

Original languageEnglish
Pages (from-to)50-59
Number of pages10
JournalCardiology
Volume125
Issue number1
DOIs
Publication statusPublished - May 2013

Fingerprint

Renin-Angiotensin System
Renin
Vasodilator Agents
Diuretics
Antihypertensive Agents
Electrolytes
Oxidative Stress
Homeostasis
Cardiovascular Diseases
Maintenance
Blood Pressure
Hypertension
Inflammation
Therapeutics
Population

Keywords

  • Angiotensin II receptor blockers
  • Angiotensin-converting enzyme inhibitors
  • Cardiovascular risk
  • Direct renin inhibitors
  • Plasma renin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Plasma renin and cardiovascular risk : What is the evidence for an association? / Volpe, Massimo; Unger, Thomas.

In: Cardiology, Vol. 125, No. 1, 05.2013, p. 50-59.

Research output: Contribution to journalArticle

@article{46a89fdbe089478e994f73ad45ef45ce,
title = "Plasma renin and cardiovascular risk: What is the evidence for an association?",
abstract = "Renin is a key component of the renin-angiotensin system (RAS), which plays an important role in the maintenance of blood pressure and electrolyte-volume homeostasis. RAS also plays a role in cardiovascular (CV) disease as a result of effects on inflammation and oxidative stress. There is growing evidence that plasma renin activity may be a marker of CV risk in hypertensive patients. This increase in CV risk likely reflects activation of the RAS as a whole. Patients undergoing treatment for hypertension experience a reactive increase in renin, especially if treated with diuretics, vasodilators or agents that block the RAS. There is not sufficient evidence, however, that this reactive increase in renin is intrinsically harmful for hypertensive patients in whom adequate levels of RAS blockade have been achieved. Indeed, in such patients, additional RAS blockade may not be beneficial and may even increase the risk of adverse events. Plasma renin may be an important prognostic indicator in untreated patients, and one that can be used to help in the choice of antihypertensive treatment. Currently, however, the link between plasma renin and CV risk in treated patients is inconsistent between different populations and in various clinical conditions, calling for further investigation.",
keywords = "Angiotensin II receptor blockers, Angiotensin-converting enzyme inhibitors, Cardiovascular risk, Direct renin inhibitors, Plasma renin",
author = "Massimo Volpe and Thomas Unger",
year = "2013",
month = "5",
doi = "10.1159/000348365",
language = "English",
volume = "125",
pages = "50--59",
journal = "Cardiology",
issn = "0008-6312",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Plasma renin and cardiovascular risk

T2 - What is the evidence for an association?

AU - Volpe, Massimo

AU - Unger, Thomas

PY - 2013/5

Y1 - 2013/5

N2 - Renin is a key component of the renin-angiotensin system (RAS), which plays an important role in the maintenance of blood pressure and electrolyte-volume homeostasis. RAS also plays a role in cardiovascular (CV) disease as a result of effects on inflammation and oxidative stress. There is growing evidence that plasma renin activity may be a marker of CV risk in hypertensive patients. This increase in CV risk likely reflects activation of the RAS as a whole. Patients undergoing treatment for hypertension experience a reactive increase in renin, especially if treated with diuretics, vasodilators or agents that block the RAS. There is not sufficient evidence, however, that this reactive increase in renin is intrinsically harmful for hypertensive patients in whom adequate levels of RAS blockade have been achieved. Indeed, in such patients, additional RAS blockade may not be beneficial and may even increase the risk of adverse events. Plasma renin may be an important prognostic indicator in untreated patients, and one that can be used to help in the choice of antihypertensive treatment. Currently, however, the link between plasma renin and CV risk in treated patients is inconsistent between different populations and in various clinical conditions, calling for further investigation.

AB - Renin is a key component of the renin-angiotensin system (RAS), which plays an important role in the maintenance of blood pressure and electrolyte-volume homeostasis. RAS also plays a role in cardiovascular (CV) disease as a result of effects on inflammation and oxidative stress. There is growing evidence that plasma renin activity may be a marker of CV risk in hypertensive patients. This increase in CV risk likely reflects activation of the RAS as a whole. Patients undergoing treatment for hypertension experience a reactive increase in renin, especially if treated with diuretics, vasodilators or agents that block the RAS. There is not sufficient evidence, however, that this reactive increase in renin is intrinsically harmful for hypertensive patients in whom adequate levels of RAS blockade have been achieved. Indeed, in such patients, additional RAS blockade may not be beneficial and may even increase the risk of adverse events. Plasma renin may be an important prognostic indicator in untreated patients, and one that can be used to help in the choice of antihypertensive treatment. Currently, however, the link between plasma renin and CV risk in treated patients is inconsistent between different populations and in various clinical conditions, calling for further investigation.

KW - Angiotensin II receptor blockers

KW - Angiotensin-converting enzyme inhibitors

KW - Cardiovascular risk

KW - Direct renin inhibitors

KW - Plasma renin

UR - http://www.scopus.com/inward/record.url?scp=84876798157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876798157&partnerID=8YFLogxK

U2 - 10.1159/000348365

DO - 10.1159/000348365

M3 - Article

C2 - 23636010

AN - SCOPUS:84876798157

VL - 125

SP - 50

EP - 59

JO - Cardiology

JF - Cardiology

SN - 0008-6312

IS - 1

ER -